Biowaiver monographs for immediate release solid oral dosage forms: efavirenz

Area of Science:

• Pharmaceutical Sciences
• Drug Development
• Regulatory Science

Background:

• Efavirenz, an antiretroviral agent, presents challenges in formulation due to its biopharmaceutical properties.
• Its classification within the Biopharmaceutics Classification System (BCS) is complex, often falling into Class II or IV.
• Variability in absorption can be influenced by excipients and manufacturing processes.

Purpose of the Study:

• To review literature regarding the suitability of biowaivers for efavirenz immediate-release (IR) solid oral dosage forms.
• To assess the scientific justification for waiving in vivo bioequivalence testing for efavirenz-containing products.

Main Methods:

• Comprehensive literature review of studies on efavirenz's solubility, permeability, dissolution, and absorption.
• Analysis of efavirenz's classification under the Biopharmaceutics Classification System (BCS).
• Evaluation of factors affecting efavirenz absorption and the implications of therapeutic variability.

Main Results:

• Efavirenz exhibits poor solubility and does not meet 'high solubility' criteria, classifying it as BCS Class II/IV.
• The innovator product fails to meet 'rapidly dissolving' criteria.
• Product variations and excipients significantly impact efavirenz absorption rates and extent.

Conclusions:

• A biowaiver for efavirenz IR solid oral dosage forms is not scientifically supported.
• Concerns include variable absorption, potential for subtherapeutic levels, treatment failure, and development of drug resistance.
• Regulatory decisions regarding biowaivers must consider these critical factors for efavirenz products.